FHTX
FHTX
NASDAQ · Biotechnology

Foghorn Therapeutics Inc

$4.76
+0.01 (+0.21%)
As of May 9, 1:54 AM ET ·
Financial Highlights (FY 2026)
Revenue
25.42M
Net Income
-61,091,414
Gross Margin
Profit Margin
-240.3%
Rev Growth
+17.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 35.6% 35.6%
Operating Margin -279.5% -251.5% 5.1% 4.9%
Profit Margin -240.3% -228.3% 4.9% 5.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 25.42M 21.70M 271.86M 230.16M
Gross Profit 96.87M 82.01M
Operating Income -71,048,197 -54,587,141 13.80M 11.27M
Net Income -61,091,414 -46,937,231 13.33M 11.49M
Gross Margin 35.6% 35.6%
Operating Margin -279.5% -251.5% 5.1% 4.9%
Profit Margin -240.3% -228.3% 4.9% 5.0%
Rev Growth +17.1% +17.1% -6.6% +8.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 139.92M 178.86M
Total Equity 241.00M 245.51M
D/E Ratio 0.58 0.73
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -65,540,547 -53,153,081 20.13M 16.16M
Free Cash Flow 11.27M 12.60M